



BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

- Prior authorization for a non-preferred agent in any category will be given only if there has been a trial of the preferred brand/generic equivalent or preferred formulation of the active ingredient, at a therapeutic dose, that resulted in a partial response with a documented intolerance.
- Prior authorization of a non-preferred isomer, pro-drug, or metabolite will be considered with a trial of a preferred parent drug of the same chemical entity, at a therapeutic dose, that resulted in a partial response with documented intolerance or a previous trial and therapy failure, at a therapeutic dose, with a preferred drug of a different chemical entity indicated to treat the submitted diagnosis. (The required trial may be overridden when documented evidence is provided that the use of these preferred agent(s) would be medically contraindicated.)
- Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC drugs are not covered unless specified.
- PA criteria for non-preferred agents apply in addition to general Drug Utilization Review policy that is in effect for the entire pharmacy program, including, but not limited to, appropriate dosing, duplication of therapy, etc.
- The use of pharmaceutical samples will not be considered when evaluating the members' medical condition or prior prescription history for drugs that require prior authorization.
- Acronyms
 - CL - Requires clinical PA. For detailed clinical criteria, please refer to:
<http://www.dhhr.wv.gov/bms/Pharmacy/Pages/PriorAuthorizationCriteria.aspx>
 - NR - New drug has not been reviewed by P & T Committee
 - AP - Non-preferred and selected preferred drugs, where indicated, are subject to auto-PA criteria. See PA criteria column.



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ACNE AGENTS (Topical)^{AP}			
ANTI-INFECTIVE			
	AKNE-MYCIN (erythromycin) AZELEX (azelaic acid) clindamycin erythromycin sodium sulfacetamide	ACZONE (dapson) CLEOCIN-T (clindamycin) EVOCLIN (clindamycin) KLARON (sodium sulfacetamide)	Thirty (30) day trials each of one preferred retinoid and two unique chemical entities in two other subclasses, including the generic version of a requested non-preferred product, are required before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. (In cases of pregnancy, a trial of retinoids will not be required.)
RETINOIDS			
	RETIN A liquid & Micro (tretinoin) TAZORAC (tazarotene) tretinoin cream, gel	adapalene AVITA (tretinoin) DIFFERIN (adapalene) RETIN-A cream, gel (tretinoin) TRETIN-X (tretinoin)	PA required after 17 years of age for tretinoin products.
KERATOLYTICS (Benzoyl Peroxides)			
	benzoyl peroxide ETHEXDERM (benzoyl peroxide) OSCION (benzoyl peroxide)	BENZAC WASH (benzoyl peroxide) BENZEFOAM (benzoyl peroxide) BENZEFOAM ULTRA (benzoyl peroxide) BREVOXYL (benzoyl peroxide) DESQUAM (benzoyl peroxide) LAVOCLEN (benzoyl peroxide) TRIAZ (benzoyl peroxide)	Acne kits are non-preferred.
COMBINATION AGENTS			
	benzoyl peroxide/urea erythromycin/benzoyl peroxide sulfacetamide sodium/sulfur wash/cleanser	ACANYA (clindamycin phosphate/benzoyl peroxide) AVAR (sulfur/sulfacetamide) BENZACLIN GEL (benzoyl peroxide/clindamycin) BENZAMYCIN PAK (benzoyl peroxide/erythromycin) benzoyl peroxide/clindamycin gel	Thirty (30) day trials each of one preferred retinoid and two unique chemical entities in two other subclasses, including the generic version of a requested non-preferred product, are required before a non-preferred agent will be authorized unless one of the exceptions on the PA form is



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID**

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		CLENIA (sulfacetamide sodium/sulfur) DUAC CS (benzoyl peroxide/ clindamycin) EPIDUO (adapalene/benzoyl peroxide) INOVA 4/1 (benzoyl peroxide/salicylic acid) NUOX (benzoyl peroxide/sulfur) PLEXION (sulfacetamide sodium/sulfur) PRASCION (sulfacetamide sodium/sulfur) ROSADERM (sulfacetamide sodium/sulfur) ROSANIL (sulfacetamide sodium/sulfur) ROSULA (sulfacetamide sodium/sulfur/ urea) sulfacetamide sodium/sulfur lotion, gel, pad sulfacetamide sodium/sulfur/ urea SULFOXYL (benzoyl peroxide/sulfur) SULFATOL (sulfacetamide sodium/sulfur/urea) VELTIN (clindamycin/tretinoin) ZENCIA WASH (sulfacetamide sodium/sulfur) ZIANA (clindamycin/tretinoin)	<p>present. (In cases of pregnancy, a trial of retinoids will not be required.)</p> <p>In addition, thirty day trials of combinations of the corresponding preferred single agents available are required before non-preferred combination agents will be authorized.</p>
ALZHEIMER'S AGENTS^{AP}			
CHOLINESTERASE INHIBITORS			
	donepezil	ARICEPT (donepezil) ARICEPT 23mg (donepezil) ARICEPT ODT(donepezil) COGNEX (tacrine) donepezil ODT EXELON CAPSULE (rivastigmine) EXELON PATCH (rivastigmine) galantamine galantamine ER RAZADYNE (galantamine) RAZADYNE ER (galantamine) rivastigmine	<p>A thirty (30) day trial of a preferred agent is required before a non-preferred agent in this class will be authorized unless one of the exceptions on the PA form is present.</p> <p>Aricept 23mg tablets will be approved when there is a diagnosis of moderate-to-severe Alzheimer's Disease, a trial of donepezil 10mg daily for at least three (3) months, and donepezil 20mg daily for an additional one (1) month.</p> <p>Aricept and donepezil ODT will be approved only when the oral dosage form is not appropriate for the patient.</p>



BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
			Members currently utilizing Exelon patches as of 1/1/2012 may continue.
NMDA RECEPTOR ANTAGONIST			
	NAMENDA (memantine)		
ANALGESICS, NARCOTIC - SHORT ACTING (Non-parenteral)^{AP}			
	APAP/codeine ASA/codeine codeine dihydrocodeine/ APAP/caffeine hydrocodone/APAP hydrocodone/ibuprofen hydromorphone levorphanol morphine oxycodone oxycodone/APAP oxycodone/ASA pentazocine/APAP pentazocine/naloxone ROXICET (oxycodone/acetaminophen) tramadol tramadol/APAP	ABSTRAL (fentanyl) ACTIQ (fentanyl) butalbital/APAP/caffeine/codeine butalbital/ASA/caffeine/codeine butorphanol COMBUNOX (oxycodone/ibuprofen) DEMEROL (meperidine) DILAUDID (hydromorphone) fentanyl FENTORA (fentanyl) FIORICET W/ CODEINE (butalbital/APAP/caffeine/codeine) FIORINAL W/ CODEINE (butalbital/ASA/caffeine/codeine) LAZANDA (fentanyl) LORCET (hydrocodone/APAP) LORTAB (hydrocodone/APAP) MAGNACET (oxycodone/APAP) meperidine NUCYNTA (tapentadol) OPANA (oxymorphone) ONSOLIS (fentanyl) oxycodone/ibuprofen OXYFAST (oxycodone) OXYIR (oxycodone) PANLOR (dihydrocodeine/ APAP/caffeine) PERCOCET (oxycodone/APAP) PERCODAN (oxycodone/ASA) ROXANOL (morphine) RYBIX ODT (tramadol) TALACEN (pentazocine/APAP) TALWIN NX (pentazocine/naloxone) TREZIX (dihydrocodeine/ APAP/caffeine) ^{NR} TYLENOL W/CODEINE (APAP/codeine)	<p>Six (6) day trials of at least four (4) chemically distinct preferred agents (based on narcotic ingredient only), including the generic formulation of a requested non-preferred product, are required before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.</p> <p>Fentanyl lozenges and Onsolis will only be approved for a diagnosis of cancer and as an adjunct to a long-acting agent. Neither will be approved for monotherapy.</p> <p>Limits: Unless the patient has escalating cancer pain or another diagnosis supporting increased quantities of short-acting opioids, all short acting solid forms of the narcotic analgesics are limited to 120 tablets per 30 days for the purpose of maximizing the use of longer acting medications to prevent unnecessary breakthrough pain in chronic pain therapy.</p>



BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		ULTRACET (tramadol/APAP) ULTRAM (tramadol) VICODIN (hydrocodone/APAP) VICOPROFEN (hydrocodone/ibuprofen) VOPAC (codeine/acetaminophen) XODOL (hydrocodone/acetaminophen) ZAMICET (hydrocodone/APAP) ZYDONE (hydrocodone/acetaminophen) XOLOX (oxycodone/APAP)	
ANALGESICS, NARCOTIC - LONG ACTING (Non-parenteral)^{AP}			
	fentanyl transdermal KADIAN (morphine) 10mg, 20mg, 30mg, 50mg, 60mg, 100mg methadone morphine ER tablets OPANA ER (oxymorphone)	AVINZA (morphine) BUTRANS (buprenorphine) ^{CL} CONZIP ER (tramadol) DOLOPHINE (methadone) DURAGESIC (fentanyl) EXALGO ER (hydromorphone) EMBEDA (morphine/naltrexone) KADIAN (morphine) 80mg, 200mg morphine ER capsules MS CONTIN (morphine) NUCYNTA ER (tapentadol) ORAMORPH SR (morphine) oxycodone ER OXYCONTIN (oxycodone) oxymorphone ER RYZOLT ER (tramadol) tramadol ER ULTRAM ER (tramadol)	<p>Six (6) day trials each of two preferred unique long acting chemical entities are required before a non-preferred agent will be approved unless one of the exceptions on the PDL form is present. The generic form of the requested non-preferred agent, if available, must be tried before the non-preferred agent will be approved.</p> <p>Butrans will be approved if the following criteria are met:</p> <ol style="list-style-type: none"> 1. Diagnosis of moderate to severe chronic pain requiring continuous around-the-clock analgesia or 2. Patient cannot take oral medications and has a diagnosis of chronic pain and 3. Needs analgesic medication for an extended period of time and 4. Has had a previous trial** of a non-opioid analgesic medication and 5. Previous trial of one opioid medication** and 6. Current total daily opioid dose is ≤ 80 mg morphine equivalents daily or dose of transdermal fentanyl is ≤ 12.5 mcg/hr 7. Patient is not currently being



BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
			<p>treated with buprenorphine</p> <p>**Requirement is waived for patients who cannot swallow</p> <p><i>Dose optimization is required for achieving equivalent doses of Kadian 80mg and 200mg. AP does not apply.</i></p> <p>Exception: Oxycodone ER will be authorized if a diagnosis of cancer is submitted without a trial of the preferred agents.</p>
ANALGESICS (Topical)^{AP}			
	<p>capsaicin lidocaine lidocaine/prilocaine xylocaine</p>	<p>EMLA (lidocaine/prilocaine) FLECTOR PATCH (diclofenac) LIDODERM PATCH (lidocaine) LIDAMANTLE (lidocaine) LIDAMANTLE HC (lidocaine/hydrocortisone) LMX 4 (lidocaine) PENNSAID (diclofenac) SYNERA (lidocaine/tetracaine) VOLTAREN GEL (diclofenac) ZOSTRIX (capsaicin)</p>	<p>Ten (10) day trials of each of the preferred topical anesthetics (lidocaine, lidocaine/prilocaine, and xylocaine) are required before a non-preferred topical anesthetic will be approved unless one of the exceptions on the PA form is present.</p> <p>Lidoderm patches will be approved for a diagnosis of post-herpetic neuralgia.</p> <p>Thirty (30) day trials of each of the preferred oral NSAIDs and capsaicin are required before Voltaren Gel will be approved unless one of the exceptions on the PA form is present.</p> <p>Flector patches will be approved only for a diagnosis of acute strain, sprain or injury after a five (5) day trial of one of the preferred oral NSAIDs and for a maximum duration of 14 days unless one of the exceptions on the PA form is</p>



BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
			present.
ANDROGENIC AGENTS			
	ANDRODERM (testosterone) ANDROGEL (testosterone)	AXIRON (testosterone) FORTESTA (testosterone) TESTIM (testosterone)	The non-preferred agents will be approved only if one of the exceptions on the PA form is present.
ANGIOTENSIN MODULATORS^{AP}			
ACE INHIBITORS			
	benazepril captopril enalapril fosinopril lisinopril quinapril ramipril	ACCUPRIL (quinapril) ACEON (perindopril) ALTACE (ramipril) CAPOTEN (captopril) LOTENSIN (benazepril) MAVIK (trandolapril) moexipril MONOPRIL (fosinopril) perindopril PRINIVIL (lisinopril) trandolapril UNIVASC (moexipril) VASOTEC (enalapril) ZESTRIL (lisinopril)	Fourteen (14) day trials of each of the preferred agents in the corresponding group, with the exception of the Direct Renin Inhibitors, are required before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
ACE INHIBITOR COMBINATION DRUGS			
	benazepril/amlodipine benazepril/HCTZ captopril/HCTZ enalapril/HCTZ fosinopril/HCTZ lisinopril/HCTZ quinapril/HCTZ	ACCURETIC (quinapril/HCTZ) CAPOZIDE (captopril/HCTZ) LEXXEL (enalapril/felodipine) LOTENSIN HCT (benazepril/HCTZ) LOTREL (benazepril/amlodipine) moexipril/HCTZ PRINZIDE (lisinopril/HCTZ) TARKA (trandolapril/verapamil) trandolapril/verapamil UNIRETIC (moexipril/HCTZ) VASERETIC (enalapril/HCTZ) ZESTORETIC (lisinopril/HCTZ)	
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs)			



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
04/01/12
Version 2012.5**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	AVAPRO (irbesartan) BENICAR (olmesartan) DIOVAN (valsartan) losartan MICARDIS (telmisartan)	ATACAND (candesartan) COZAAR (losartan) EDARBI (azilsartan) eprosartan TEVETEN (eprosartan)	
	ARB COMBINATIONS		
	AVALIDE (irbesartan/HCTZ) BENICAR-HCT (olmesartan/HCTZ) DIOVAN-HCT (valsartan/HCTZ) EXFORGE (valsartan/amlodipine) EXFORGE HCT (valsartan/amlodipine/HCTZ) losartan/HCTZ MICARDIS-HCT (telmisartan/HCTZ)	ATACAND-HCT (candesartan/HCTZ) AZOR (olmesartan/amlodipine) EDARBYCLOR (azilsartan/chlorthalidone) ^{NR} HYZAAR (losartan/HCTZ) TEVETEN-HCT (eprosartan/HCTZ) TRIBENZOR (olmesartan/amlodipine/HCTZ) TWYNSTA (telmisartan/amlodipine)	
	DIRECT RENIN INHIBITORS		
	AMTURNIDE (aliskiren/amlodipine/HCTZ) ^{AP} TEKAMLO (aliskiren/amlodipine) ^{AP} TEKTURNA (aliskiren) ^{AP} TEKTURNA HCT (aliskiren/HCTZ) ^{AP} VALTURNNA (aliskiren/valsartan) ^{AP}		<p>A thirty (30) day trial of one preferred ACE, ARB, or combination agents, at the maximum tolerable dose, is required before Tekturba will be approved.</p> <p>Tekturba HCT, Valturna, Tekamlo or Amturnide will be approved if the criteria for Tekturba are met and the patient also needs the other agents in the combination.</p>
ANTIBIOTICS, GI			
	ALINIA (nitazoxanide) NEO-FRADIN (neomycin) neomycin metronidazole tablet TINDAMAX (tinidazole)	DIFICID (fidaxomicin)^{CL} FLAGYL (metronidazole) FLAGYL ER (metronidazole ER) metronidazole capsule VANCOCIN (vancomycin) XIFAXIN (rifaximin)	<p>Dificid will be approved if 1) there is a diagnosis of severe <i>C. difficile</i> infection and 2) there is no response to prior treatment with vancomycin for 10-14 days.</p> <p>Xifaxin 200 mg will be approved for traveller's diarrhea if 1) there is a diagnosis of <i>E. coli</i> diarrhea, 2) patient is between 12 and 18 years old or is 18 years or older and has failed a trial of ciprofloxacin.</p> <p>Xifaxin 550 mg will be approved for</p>



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
04/01/12
Version 2012.5**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
			hepatic encephalopathy if 1) there is a diagnosis of hepatic encephalopathy, 2) patient is 18 years or older, and 3) patient has a history of and current treatment with lactulose.
ANTIBIOTICS, INHALED			
	TOBI (tobramycin)	CAYSTON (aztreonam)	
ANTICOAGULANTS^{CL}			
INJECTABLE			
	ARIXTRA (fondaparinux) FRAGMIN (dalteparin) LOVENOX (enoxaparin)	enoxaparin fondaparinux INNOHEP (tinzaparin)	Trials of each of the preferred agents will be required before a non-preferred agent will be approved unless one of the exceptions on the PA form is present.
ORAL			
	PRADAXA (dabigatran) ^{AP} warfarin	XARELTO (rivaroxaban)	Pradaxa will be approved for the diagnosis of non-valvular atrial fibrillation.
ANTICONVULSANTS			
ADJUVANTS			
	carbamazepine CARBATROL (carbamazepine) DEPAKOTE SPRINKLE (divalproex) divalproex EC divalproex ER divalproex DR EPITOL (carbamazepine) FELBATOL (felbamate) gabapentin GABITRIL (tiagabine) levetiracetam lamotrigine lamotrigine chewable LYRICA (pregabalin) oxcarbazepine tablets	BANZEL(rufinamide) carbamazepine XR DEPAKENE (valproic acid) DEPAKOTE (divalproex) DEPAKOTE ER (divalproex) EQUETRO (carbamazepine) FANATREX SUSPENSION (gabapentin) ^{NR} felbamate GRALISE (gabapentin) HORIZANT (gabapentin) KEPPRA (levetiracetam) KEPPRA XR (levetiracetam) LAMICTAL (lamotrigine) LAMICTAL CHEWABLE (lamotrigine) LAMICTAL ODT (lamotrigine)	A fourteen (14) day trial of one of the preferred agents in the corresponding group is required for treatment naïve patients with a diagnosis of a seizure disorder before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. A thirty (30) day trial of one of the preferred agents in the corresponding group is required for patients with a diagnosis other than seizure disorders unless one of the



BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	topiramate TRILEPTAL SUSPENSION (oxcarbazepine) valproic acid zonisamide	LAMICTAL XR (lamotrigine) levetiracetam ER NEURONTIN (gabapentin) ONFI (clobazam) ^{NR} SABRIL (vigabatrin) STAVZOR (valproic acid) TEGRETOL (carbamazepine) TEGRETOL XR (carbamazepine) TOPAMAX (topiramate) TRILEPTAL TABLETS (oxcarbazepine) VIMPAT (lacosamide) ZONEGRAN (zonisamide)	<p>exceptions on the PA form is present.</p> <p>Non-preferred anticonvulsants will be approved for patients on established therapies with a diagnosis of seizure disorders with no trials of preferred agents required. In situations where AB-rated generic equivalent products are available, "Brand Medically Necessary" must be hand-written by the prescriber on the prescription in order for the brand name product to be reimbursed.</p> <p>Requests for Gralise will be authorized if the following criteria are met:</p> <ol style="list-style-type: none"> 1. Diagnosis of post herpetic neuralgia 2. Trial of a tricyclic antidepressant for a least thirty days 3. Trial of gabapentin immediate release formulation (positive response without adequate duration) 4. Request is for once daily dosing with 1800 mg. maximum daily dosage
BARBITURATES^{AP}			
	mephobarbital phenobarbital primidone	MEBARAL (mephobarbital) MYSOLINE (primidone)	
BENZODIAZEPINES^{AP}			
	clonazepam DIASTAT (diazepam rectal) diazepam tablets	diazepam rectal gel KLONOPIN (clonazepam)	
HYDANTOINS^{AP}			
	DILANTIN INFATABS (phenytoin) PEGANONE (ethotoin) phenytoin	CEREBYX (fosphenytoin) DILANTIN (phenytoin) PHENYTEK (phenytoin)	



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
SUCCINIMIDES			
	CELONTIN (methsuximide) ethosuximide ZARONTIN (ethosuximide)		
ANTIDEPRESSANTS, OTHER			
SNRIS^{AP}			
	CYMBALTA (duloxetine) venlafaxine ER capsules	EFFEXOR (venlafaxine) EFFEXOR XR (venlafaxine) PRISTIQ (desvenlafaxine) venlafaxine VENLAFAXINE ER Tablets (venlafaxine)	A six (6) week trial each of a preferred agent and an SSRI is required before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
SECOND GENERATION NON-SSRI, OTHER^{AP}			
	bupropion SR bupropion XL mirtazapine SAVELLA (milnacipran) ^{AP*} trazodone	APLENZIN (bupropion hbr) bupropion IR DESYREL (trazodone) EMSAM (selegiline) nefazodone OLEPTRO ER (trazodone) REMERNON (mirtazapine) WELLBUTRIN (bupropion) WELLBUTRIN SR (bupropion) WELLBUTRIN XL (bupropion) VIIBRYD (vilazodone hcl)	* Savella will be approved for a diagnosis of fibromyalgia or a previous thirty (30) day trial of a drug that infers fibromyalgia: gabapentin, Cymbalta, Lyrica, amitriptyline or nortriptyline.
SELECTED TCAs			
	imipramine hcl	imipramine pamoate TOFRANIL (imipramine hcl) TOFRANIL PM (imipramine pamoate)	A twelve (12) week trial of imipramine hcl is required before a non-preferred TCA will be authorized.
ANTIDEPRESSANTS, SSRIs^{AP}			
	citalopram fluoxetine fluvoxamine LEXAPRO (escitalopram) paroxetine sertraline	CELEXA (citalopram) LUVOX (fluvoxamine) LUVOX CR (fluvoxamine) PAXIL (paroxetine) PAXIL CR (paroxetine) paroxetine ER	Thirty (30) day trials each of two (2) of the preferred agents are required before a non-preferred agent will be approved unless one of the exceptions on the PA form is present. Upon hospital discharge,



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		PEXEVA (paroxetine) PROZAC (fluoxetine) RAPIFLUX (fluoxetine) SARAFEM (fluoxetine) ZOLOFT (sertraline)	patients admitted with a primary mental health diagnosis and have been stabilized on a non-preferred SSRI will receive an authorization to continue that drug.
ANTIEMETICS^{AP}			
5HT3 RECEPTOR BLOCKERS			
	ondansetron ondansetron ODT	ANZEMET (dolasetron) KYTRIL (granisetron) granisetron GRANISOL (granisetron) SANCUSO (granisetron) ZOFRAN (ondansetron) ZOFRAN ODT (ondansetron) ZUPLENZ (ondansetron)	A 3-day trial of a preferred agent is required before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. PA is required for ondansetron when limits are exceeded.
CANNABINOIDS			
		CESAMET (nabilone) dronabinol MARINOL (dronabinol)	Cesamet will be authorized only for the treatment of nausea and vomiting associated with cancer chemotherapy for patients who have failed to respond adequately to 3-day trials of conventional treatments such as promethazine or ondansetron and are over 18 years of age. Marinol will be authorized only for the treatment of anorexia associated with weight loss in patients with AIDS or cancer and unresponsive to megestrol; or for the prophylaxis of chemotherapy induced nausea and vomiting unresponsive to 3-day trials of ondansetron or promethazine for patients between the ages of 18 and 65.
SUBSTANCE P ANTAGONISTS			



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	EMEND (aprepitant)		
ANTIFUNGALS (Oral)			
	clotrimazole fluconazole* ketoconazole ^{CL} nystatin terbinafine ^{CL}	ANCOBON (flucytosine) DIFLUCAN (fluconazole) flucytosine GRIFULVIN V TABLET (griseofulvin) griseofulvin GRIS-PEG (griseofulvin) itraconazole LAMISIL (terbinafine) MYCELEX (clotrimazole) MYCOSTATIN Tablets (nystatin) NIZORAL (ketoconazole) NOXAFIL (posaconazole) ORAVIG BUCCAL (miconazole) SPORANOX (itraconazole) VFEND (voriconazole) voriconazole	Non-preferred agents will be approved only if one of the exceptions on the PA form is present. *PA is required when limits are exceeded. PA is not required for griseofulvin suspension for children up to 6 years of age for the treatment of tinea capitis.
ANTIFUNGALS (Topical)^{AP}			
ANTIFUNGALS			
	econazole ketoconazole MENTAX (butenafine) NAFTIN (naftifine) nystatin	ciclopirox ERTACZO (sertaconazole) EXELDERM (sulconazole) LOPROX (ciclopirox) MYCOSTATIN (nystatin) NIZORAL (ketoconazole) OXISTAT (oxiconazole) PEDIPIROX-4 (ciclopirox) ^{NR} PENLAC (ciclopirox) SPECTAZOLE (econazole) VUSION (miconazole/petrolatum/zinc oxide) XOLEGEL (ketoconazole)	Fourteen (14) day trials of two (2) of the preferred agents are required before one of the non-preferred agents will be authorized unless one of the exceptions on the PA form is present. If a non-preferred shampoo is requested, a fourteen (14) day trial of one preferred product (ketoconazole shampoo) is required. Oxistat cream will be approved for children 12 and under for tinea corporis, tinea cruris, tinea pedis, and tinea (pityriasis) versicolor.
ANTIFUNGAL/STEROID COMBINATIONS			
	clotrimazole/betamethasone nystatin/triamcinolone	KETOCON PLUS (ketoconazole/hydrocortisone) LOTRISONE (clotrimazole/betamethasone) ^{AP} MYCOLOG (nystatin/triamcinolone) ^{AP}	



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID**

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ANTIHISTAMINES, MINIMALLY SEDATING^{AP}			
ANTIHISTAMINES			
	ALAVERT (loratadine) cetirizine loratadine TAVIST-ND (loratadine)	ALLEGRA (fexofenadine) CLARINEX Tablets (desloratadine) CLARINEX REDITABS (desloratadine) CLARINEX Syrup (desloratadine) CLARITIN (loratadine) fexofenadine (Rx and OTC) levocetirizine XYZAL (levocetirizine) ZYRTEC (Rx and OTC) (cetirizine) ZYRTEC SYRUP (cetirizine)	Thirty (30) day trials of at least two (2) chemically distinct preferred agents (in the age appropriate form), including the generic formulation of a requested non-preferred product, are required before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
ANTIHISTAMINE/DECONGESTANT COMBINATIONS			
	ALAVERT-D (loratadine/pseudoephedrine) cetirizine/pseudoephedrine loratadine/pseudoephedrine SEMPREX-D (acrivastine/ pseudoephedrine)	ALLEGRA-D (fexofenadine/ pseudoephedrine) CLARINEX-D (desloratadine/ pseudoephedrine) CLARITIN-D (loratadine/pseudoephedrine) fexofenadine/ pseudoephedrine (Rx and OTC) ZYRTEC-D (cetirizine/pseudoephedrine)	
ANTIMIGRAINE AGENTS, TRIPTANS^{AP}			
TRIPTANS			
	IMITREX NASAL SPRAY(sumatriptan) IMITREX INJECTION (sumatriptan) ^{CL} naratriptan sumatriptan	AMERGE (naratriptan) AXERT (almotriptan) FROVA (frovatriptan) IMITREX tablets (sumatriptan) MAXALT (rizatriptan) MAXALT MLT (rizatriptan) RELPAX (eletriptan) sumatriptan nasal spray/injection* ZOMIG (zolmitriptan)	Three (3) day trials of each unique chemical entity of the preferred agents are required before a non-preferred agent will be approved unless one of the exceptions on the PA form is present. Quantity limits apply for this drug class. *AP does not apply to nasal spray or injectable sumatriptan.
TRIPTAN COMBINATIONS			
		TREXIMET (sumatriptan/naproxen sodium)	



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA	
ANTIPARKINSON'S AGENTS (Oral)				
ANTICHOLINERGICS				
	benztropine trihexyphenidyl	COGENTIN (benztropine)	Patients starting therapy on drugs in this class must show a documented allergy to all of the preferred agents, in the corresponding class, before a non-preferred agent will be authorized.	
COMT INHIBITORS				
		COMTAN (entacapone) TASMAR (tolcapone)		
DOPAMINE AGONISTS				
	pramipexole ropinirole	MIRAPEX (pramipexole) MIRAPEX ER (pramipexole) REQUIP (ropinirole) REQUIP XL (ropinirole)	Mirapex, Mirapex ER, Requip, and Requip XL will be approved for a diagnosis of Parkinsonism with no trials of preferred agents required.	
OTHER ANTIPARKINSON'S AGENTS				
	amantadine ^{AP} bromocriptine carbidopa/levodopa selegiline STALEVO (levodopa/carbidopa/entacapone)	AZILECT (rasagiline) ELDEPRYL (selegiline) levodopa/carbidopa ODT LODOSYN (carbidopa) PARCOPA (levodopa/carbidopa) SINEMET (levodopa/carbidopa) ZELAPAR (selegiline)	Amantadine will be approved only for a diagnosis of Parkinsonism.	
ANTIPSYCHOTICS, ATYPICAL				
SINGLE INGREDIENT				
	clozapine GEODON (ziprasidone) INVEGA (paliperidone) INVEGA SUSTENNA (paliperidone)* risperidone risperidone ODT risperidone solution SEROQUEL (quetiapine) ^{AP (25mg Tablet Only)}	ABILIFY (aripiprazole) CLOZARIL (clozapine) FANAPT (iloperidone) FAZACLO (clozapine) LATUDA (lurasidone) olanzapine olanzapine IM* RISPERDAL (risperidone) RISPERDAL CONSTA (risperidone)* RISPERDAL ODT (risperidone) RISPERDAL SOLUTION (risperidone) SAPHRIS (asenapine) SEROQUEL XR (quetiapine) ZYPREXA (olanzapine)	A fourteen (14) day trial of a preferred agent is required for treatment naïve patients before a non-preferred agent will be approved unless one of the exceptions on the PA form is present. Upon discharge, a hospitalized patient stabilized on a non-preferred agent may receive authorization to continue this drug for labeled indications and at recommended dosages. Claims for Seroquel 25 mg will be	



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		ZYPREXA INTRAMUSCULAR (olanzapine)*	<p>approved:</p> <ol style="list-style-type: none"> for a diagnosis of schizophrenia or for a diagnosis of bipolar disorder or when prescribed concurrently with other strengths of Seroquel in order to achieve therapeutic treatment levels. <p>Seroquel 25 mg. will not be approved for use as a sedative hypnotic.</p> <p>All antipsychotic agents require prior authorization for children up to six (6) years of age.</p> <p>Abilify will be approved for children between the ages of 6-17 for irritability associated with autism. Abilify will be prior authorized for MDD if the following criteria are met:</p> <ol style="list-style-type: none"> The patient is at least 18 years of age. Diagnosis of Major Depressive Disorder (MDD), Evidence of trials of appropriate therapeutic duration (30 days), at the maximum tolerable dose, of at least one agent in two of the following classes: SSRI, SNRI or bupropion in conjunction with Seroquel at doses of 150 mg or more Prescribed in conjunction with an SSRI, SNRI, or bupropion The daily dose does not exceed 15 mg.

DRAFT



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
			*All injectable antipsychotic products require clinical prior authorization.
	ATYPICAL ANTIPSYCHOTIC/SSRI COMBINATIONS		
		SYMBYAX (olanzapine/fluoxetine)	
ANTIVIRALS (Oral)			
	ANTI HERPES		
	acyclovir VALTREX (valacyclovir)	famciclovir FAMVIR (famciclovir) valacyclovir ZOVIRAX (acyclovir)	Five (5) day trials each of the preferred agents are required before the non-preferred agents will be authorized unless one of the exceptions on the PA form is present.
	ANTI INFLUENZA		
	RELENZA (zanamivir) TAMIFLU (oseltamivir)	FLUMADINE (rimantadine) rimantadine amantadine ^{AP}	The anti influenza agents will be approved only for a diagnosis of influenza.
ANTIVIRALS (Topical)^{AP}			
	ABREVA (docosanol) DENA VIR (penciclovir)	ZOVIRAX (acyclovir)	Five day trials of each of the preferred agents are required before the non-preferred agent will be approved.
ATOPIC DERMATITIS			
	ELIDEL (pimecrolimus) ^{AP}	PROTOPIC (tacrolimus)	A thirty (30) day trial of a preferred medium or high potency topical corticosteroid is required before coverage of Elidel will be considered; additionally, a thirty (30) day trial of Elidel is required before Protopic will be considered, unless one of the exceptions on the PA form is present.
BETA BLOCKERS (Oral) & MISCELLANEOUS ANTIANGINALS (Oral)^{AP}			
	BETA BLOCKERS		
	acebutolol atenolol betaxolol	BETAPACE (sotalol) BLOCADREN (timolol) BYSTOLIC (nebivolol)	Fourteen (14) day trials each of three (3) chemically distinct preferred agents, including the



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	bisoprolol metoprolol metoprolol ER nadolol pindolol propranolol propranolol ER sotalol timolol	CARTROL (carteolol) CORGARD (nadolol) INDERAL LA (propranolol) INNOPRAN XL (propranolol) KERLONE (betaxolol) LEVATOL (penbutolol) LOPRESSOR (metoprolol) SECTRAL (acebutolol) TENORMIN (atenolol) TOPROL XL (metoprolol) ZEBETA (bisoprolol)	generic formulation of a requested non-preferred product, are required before one of the non-preferred agents will be approved unless one of the exceptions on the PA form is present.
BETA BLOCKER/DIURETIC COMBINATION DRUGS			
	atenolol/chlorthalidone bisoprolol/HCTZ metoprolol/HCTZ nadolol/bendroflumethiazide propranolol/HCTZ	CORZIDE (nadolol/bendroflumethiazide) DUTOPROL (metoprolol ER/HCTZ ER)^{NR} INDERIDE (propranolol/HCTZ) LOPRESSOR HCT (metoprolol/HCTZ) TENORETIC (atenolol/chlorthalidone) ZIAC (bisoprolol/HCTZ)	
BETA- AND ALPHA-BLOCKERS			
	carvedilol labetalol	COREG (carvedilol) COREG CR (carvedilol) TRANDATE (labetalol)	
ANTIANGINALS			
		RANEXA (ranolazine) ^{AP}	Ranexa will be approved for patients with angina who are also taking a calcium channel blocker, a beta blocker, or a nitrite as single agents or a combination agent containing one of these ingredients.
BLADDER RELAXANT PREPARATIONS^{AP}			
	oxybutynin oxybutynin ER TOVIAZ (fesoterodine) VESICARE (solifenacin)	ENABLEX (darifenacin) DETROL (tolterodine) DETROL LA (tolterodine) DITROPAN (oxybutynin) DITROPAN XL (oxybutynin) GELNIQUE (oxybutynin) OXYTROL (oxybutynin) SANCTURA (trospium) SANCTURA XR (trospium) trospium	A thirty (30) day trial each of the chemically distinct preferred agents is required before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.



BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
BONE RESORPTION SUPPRESSION AND RELATED AGENTS			
BISPHOSPHONATES			
	alendronate FOSAMAX SOLUTION (alendronate)	ACTONEL (risedronate) ACTONEL WITH CALCIUM (risedronate/ calcium) ATELVIA (risedronate) BONIVA (ibandronate) DIDRONEL (etidronate) FOSAMAX TABLETS (alendronate) FOSAMAX PLUS D (alendronate/vitamin D) ZOMETA (zoledronic acid)	A 30-day trial of the preferred agent is required before a non-preferred agent will be approved.
OTHER BONE RESORPTION SUPPRESSION AND RELATED AGENTS			
	MIACALCIN (calcitonin)	calcitonin EVISTA (raloxifene) FORTEO (teriparatide) FORTICAL (calcitonin)	Evista will be approved for postmenopausal women with osteoporosis or at high risk for invasive breast cancer.
BPH AGENTS^{AP}			
5-ALPHA-REDUCTASE (5AR) INHIBITORS			
	AVODART (dutasteride) finasteride	PROSCAR (finasteride)	Thirty (30) day trials each of at least two (2) chemically distinct preferred agents, including the generic formulation of a requested non-preferred agent, are required before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
ALPHA BLOCKERS			
	doxazosin tamsulosin terazosin	alfuzosin CARDURA (doxazosin) CARDURA XL (doxazosin) FLOMAX (tamsulosin) HYTRIN (terazosin) RAPAFLO (silodosin) UROXATRAL (alfuzosin)	
5-ALPHA-REDUCTASE (5AR) INHIBITORS/ALPHA BLOCKER COMBINATION			



BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		JALYN (dutasteride/tamsulosin)	Thirty (30) day trials of dutasteride and tamsulosin concurrently are required before the non-preferred agent will be approved.
BRONCHODILATORS & RESPIRATORY DRUGS			
ANTICHOLINERGIC			
	ATROVENT HFA (ipratropium) ipratropium SPIRIVA (tiotropium)		Thirty (30) day trials each of the preferred agents in the corresponding group are required before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
ANTICHOLINERGIC-BETA AGONIST COMBINATIONS			
	COMBIVENT (albuterol/ipratropium)	albuterol/ipratropium DUONEB (albuterol/ipratropium)	For severely compromised patients, albuterol/ipratropium will be approved if the combined volume of albuterol and ipratropium nebulas is inhibitory.
PDE4 INHIBITOR			
		DALIRESP (roflumilast)	Daliresp will be approved when the following criteria are met: 1. Patient is ≥ forty (40) years of age and 2. Diagnosis of severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and multiple exacerbations requiring systemic glucocorticoids in the preceding six (6) months and 3. Concurrent therapy with an inhaled corticosteroid and long-acting bronchodilator and evidence of compliance and 4. No evidence of moderate to severe liver impairment (Child-Pugh Class B or C) and 5. No concurrent use with strong cytochrome P450 inhibitors



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
			(rimampicin, phenobarbital, carbamazepine or phenytoin).
INHALATION SOLUTION			
	albuterol 2.5mg/0.5mL	ACCUNEB (albuterol)** albuterol 0.63mg & 1.25mg/3mL ^{AP} BROVANA (arformoterol) levalbuterol metaproterenol PERFOROMIST (formoterol) XOPENEX (levalbuterol)	Thirty (30) day trials each of the chemically distinct preferred agents in their corresponding groups are required before a non-preferred agent in that group will be authorized unless one of the exceptions on the PA form is present. **No PA is required for ACCUNEB for children up to 5 years of age.
INHALERS, LONG-ACTING			
	FORADIL (formoterol) SEREVENT (salmeterol)	ARCAPTA (indacaterol maleate)	
INHALERS, SHORT-ACTING			
	MAXAIR (pirbuterol) PROAIR HFA (albuterol) PROVENTIL HFA (albuterol) VENTOLIN HFA (albuterol)	XOPENEX HFA (levalbuterol)	Xopenex Inhalation Solution will be approved for 12 months for a diagnosis of asthma or COPD for patients on concurrent asthma controller therapy (either oral or inhaled) with documentation of failure on a trial of albuterol or documented intolerance of albuterol, or for concurrent diagnosis of heart disease.
ORAL			
	albuterol terbutaline	metaproterenol VOSPIRE ER (albuterol)	
CALCIUM CHANNEL BLOCKERS^{AP}			
LONG-ACTING			
	amlodipine diltiazem XR, XT felodipine ER nifedipine ER nisoldipine	ADALAT CC (nifedipine) CALAN SR (verapamil) CARDENE SR (nicardipine) CARDIZEM CD, LA, SR (diltiazem) COVERA-HS (verapamil)	Fourteen (14) day trials each of the preferred agents are required before a non-preferred agent will be approved unless one of the exceptions on the PA form is



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID**

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	verapamil ER	DILACOR XR (diltiazem) DYNACIRC CR (isradipine) ISOPTIN SR (verapamil) NORVASC (amlodipine) PLENDIL (felodipine) PROCARDIA XL (nifedipine) SULAR (nisoldipine) TIAZAC (diltiazem) VERELAN/VERELAN PM (verapamil)	present.
SHORT-ACTING			
	diltiazem verapamil	CALAN (verapamil) CARDENE (nicardipine) CARDIZEM (diltiazem) DYNACIRC (isradipine) isradipine nicardipine nimodipine nifedipine NIMOTOP (nimodipine) PROCARDIA (nifedipine)	
CEPHALOSPORINS AND RELATED ANTIBIOTICS (Oral)^{AP}			
BETA LACTAMS AND BETA LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS			
	amoxicillin/clavulanate	amoxicillin/clavulanate ER AUGMENTIN XR (amoxicillin/clavulanate) MOXATAG (amoxicillin)	A five (5) day trial of the preferred agent is required before a non-preferred agent is authorized unless one of the exceptions on the PA form is present.
CEPHALOSPORINS			
	cefaclor cefadroxil cefdinir cefditoren cefpodoxime cefprozil cefuroxime cephalexin SPECTRACEF (cefditoren)	CECLOR (cefaclor) CEDAX (ceftibuten) CEFTIN (cefuroxime) CEFZIL (cefprozil) DURICEF (cefadroxil) KEFLEX (cephalexin) OMNICEF (cefdinir) PANIXINE (cephalexin) RANICLOR (cefaclor) SUPRAX (cefixime) VANTIN (cefpodoxime)	



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
COLONY STIMULATING FACTORS			
	LEUKINE (sargramostim) NEUPOGEN (filgrastim)	NEULASTA (filgrastim)	
COUGH & COLD/1ST GENERATION ANTIHISTAMINES			
ANTIHISTAMINES, 1ST GENERATION			
	chlorpheniramine clemastine diphenhydramine		See posted list of covered NDCs.
ANTITUSSIVE-ANTIHISTAMINE COMBINATIONS			
	dextromethorphan HBR/promethazine		See posted list of covered NDCs.
ANTIHISTAMINE-ANTITUSSIVE-DECONGESTANT COMBINATIONS			
	brompheniramine/dextromethorphan HBR/pseudoephedrine chlorpheniramine/dextromethorphan/ pseudoephedrine		See posted list of covered NDCs.
ANTITUSSIVE-NON-NARCOTIC			
	DELSYM (dextromethorphan polistirex)		See posted list of covered NDCs.
DECONGESTANTS			
	phenylephrine pseudoephedrine		See posted list of covered NDCs.
ANTITUSSIVES/EXPECTORANTS			
	guaifenesin guaifenesin/dextromethorphan		See posted list of covered NDCs.
DECONGESTANT-ANTIHISTAMINE-ANTICHOLINERGIC COMBINATIONS			
	pseudoephedrine/chlorpheniramine/ scopolamine syrup		See posted list of covered NDCs.
DECONGESTANT-ANTIHISTAMINE COMBINATIONS			



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID**

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	phenylephrine HCL/chlorpheniramine maleate syrup/drops phenylephrine HCL/promethazine syrup		See posted list of covered NDCs.
NARCOTIC ANTITUSSIVE-EXPECTORANT COMBINATION			
CYTOKINE & CAM ANTAGONISTS^{CL}			
	ENBREL (etanercept) HUMIRA (adalimumab)	CIMZIA (certolizumab/pegol) KINERET (anakinra) ORENCIA (abatacept) SUBCUTANEOUS SIMPONI (golimumab)	Thirty day trials of each of the preferred agents are required before a non-preferred agent will be approved. See additional criteria for treatment of psoriasis or psoriatic arthritis at http://www.dhhr.wv.gov/bms/Pharmacy/Pages/pac.aspx
ERYTHROPOIESIS STIMULATING PROTEINS^{CL}			
	PROCRIT (rHuEPO)	ARANESP (darbepoetin) EPOGEN (rHuEPO)	A thirty (30) day trial of the preferred agent is required before a non-preferred agent will be approved. Prior authorization will be given for the erythropoiesis agents if the following criteria are met: 1. Hemoglobin or Hematocrit less than 10/30 respectively. For renewal, hemoglobin or hematocrit levels greater than 12/36 will require dosage reduction or discontinuation. Exceptions will be considered on an individual basis after medical documentation is reviewed. (Laboratory values must be dated within six (6) weeks of request.) 2. Transferrin saturation \geq 20%, ferritin levels \geq 100 mg/ml, or on concurrent therapeutic iron therapy.



BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
			<p>(Laboratory values must be dated within three (3) weeks of request. For re-authorization, transferrin saturation or ferritin levels are not required if the patient has been responsive to the erythropoietin agent.</p> <p>3. For HIV-infected patients, endogenous serum erythropoietin level must be $\leq 500\text{mU/ml}$ to initiate therapy.</p> <p>4. No evidence of untreated GI bleeding, hemolysis, or Vitamin B-12, iron or folate deficiency.</p>
FLUOROQUINOLONES (Oral)^{AP}			
	CIPRO (ciprofloxacin) Suspension ciprofloxacin ciprofloxacin ER levofloxacin	AVELOX (moxifloxacin) CIPRO (ciprofloxacin) Tablets CIPRO XR (ciprofloxacin) FACTIVE (gemifloxacin) FLOXIN (ofloxacin) LEVAQUIN (levofloxacin) NOROXIN (norfloxacin) ofloxacin PROQUIN XR (ciprofloxacin)	A five (5) day trial of one of the preferred agents is required before a non-preferred agent will be approved unless one of the exceptions on the PA form is present.
GENITAL WARTS AGENTS			
	ALDARA (imiquimod)	CONDYLOX (podofilox) imiquimod podofilox VEREGEN (sinecatechins) ZYCLARA (imiquimod)	A thirty (30) day trial of the preferred agent is required before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. Zyclara will be approved for a diagnosis of actinic keratosis.
GLUCOCORTICOIDS (Inhaled)^{AP}			
GLUCOCORTICOIDS			



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID**

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	AEROBID (flunisolide) AEROBID-M (flunisolide) ASMANEX (mometasone) FLOVENT HFA (fluticasone) FLOVENT Diskus (fluticasone) QVAR (beclomethasone)	ALVESCO (ciclesonide) budesonide PULMICORT (budesonide)*	<p>Thirty (30) day trials each of the preferred agents are required before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.</p> <p>Pulmicort Respules do not require a prior authorization for children through 8 years of age or for individuals unable to use an MDI. When children who have been stabilized on Pulmicort Respules reach age 9, prescriptions for the Pulmicort inhaler will be authorized for them.</p> <p>*For children less than 9 years of age and for those who meet the PA requirements, brand Pulmicort is preferred over the generic.</p>
GLUCOCORTICOID/BRONCHODILATOR COMBINATIONS			
	ADVAIR (fluticasone/salmeterol) ADVAIR HFA (fluticasone/salmeterol) DULERA (mometasone/formoterol) SYMBICORT(budesonide/formoterol)		
GLUCOCORTICIDS (Topical)			
VERY HIGH & HIGH POTENCY			
	betamethasone dipropionate cream/ointment betamethasone dipropionate/propylene glycol betamethasone valerate ointment clobetasol propionate cream/gel/ointment/solution clobetasol propionate/emollient desoximetasone cream/gel/ointment fluocinonide halobetasol propionate triamcinolone acetonide 0.5%	amcinonide APEXICON (diflorasone diacetate) APEXICON E (diflorasone diacetate) betamethasone dipropionate gel clobetasol propionate foam, lotion, shampoo CLOBEX (clobetasol propionate) CORMAX (clobetasol propionate) difflorasone diacetate difflorasone diacetate/emollient DIPROLENE (betamethasone dipropionate/propylene glycol) DIPROLENE AF (betamethasone dipropionate/propylene glycol)	<p>Five day trials of one form of each preferred unique active ingredient in the corresponding potency group are required before a non-preferred agent will be approved.</p>



BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		DIPROSONE (betamethasone dipropionate) fluocinonide/emollient halcinonide HALOG (halcinonide) KENALOG 0.5% (triamcinolone acetonide) LIDEX (fluocinonide) LIDEX-E (fluocinonide) LUXIQ (betamethasone valerate) OLUX (clobetasol propionate) OLUX-E (clobetasol propionate/emollient) PSORCON (diflorasone diacetate) TEMOVATE (clobetasol propionate) TEMOVATE-E (clobetasol propionate/emollient) TOPICORT (desoximetasone) ULTRAVATE (halobetasol propionate) VANOS (fluocinonide)	
MEDIUM POTENCY			
	betamethasone dipropionate lotion betamethasone valerate cream desoximetasone 0.05% cream fluocinolone acetonide 0.025% fluticasone propionate hydrocortisone valerate mometasone furoate triamcinolone acetonide 0.025% and 0.1%	ARISTOCORT (triamcinolone) betamethasone valerate lotion BETA-VAL (betamethasone valerate) CLODERM (clocortolone pivalate) CORDRAN/CORDRAN SP (flurandrenolide) CUTIVATE (fluticasone propionate) DERMATOP (prednicarbate) ELOCON (mometasone furoate) hydrocortisone butyrate hydrocortisone butyrate/emollient KENALOG 0.1% (triamcinolone acetonide) LOCOID (hydrocortisone butyrate) LOCOID LIPOCREAM (hydrocortisone butyrate/emollient) prednicarbate TOPICORT LP (desoximetasone) TRIDERM (triamcinolone acetonide) WESTCORT (hydrocortisone valerate)	
LOW POTENCY			
	desonide fluocinolone acetonide 0.01% hydrocortisone 0.5%, 1%, 2.5% hydrocortisone acetate 0.5%, 1% (Rx & OTC)	ACLOVATE (alclometasone dipropionate) alclometasone dipropionate CAPEX (fluocinolone acetonide) DERMA-SMOOTH FS (fluocinolone)	



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID**

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		acetonide) DESONATE (desonide) DESOWEN (desonide) LOKARA (desonide) PANDEL (hydrocortisone probutate) VERDESO (desonide)	
GROWTH HORMONE^{CL}			
	GENOTROPIN (somatropin) NORDITROPIN NORDIFLEX (somatropin) NORDITROPIN FLEXPPO (somatropin) NUTROPIN AQ NUSPIN (somatropin)	HUMATROPE (somatropin) INCRELEX (mecasermin) NUTROPIN (somatropin) NUTROPIN AQ (somatropin) OMNITROPE (somatropin) SAIZEN (somatropin) SEROSTIM (somatropin) TEV-TROPIN (somatropin) ZORBTIVE (somatropin)	The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. Patients already on a non-preferred agent will receive authorization to continue therapy on that agent for the duration of the existing PA.
H. PYLORI COMBINATION TREATMENTS			
	Please use individual components: preferred PPI (Dexilant, omeprazole or pantoprazole) amoxicillin tetracycline metronidazole clarithromycin bismuth	HELIDAC (bismuth/metronidazole/tetracycline) PREVPAC (lansoprazole/amoxicillin/clarithromycin) PYLERA (bismuth/metronidazole/tetracycline)	A trial of all the individual preferred components (with Dexilant, omeprazole or pantoprazole) at the recommended dosages, frequencies and duration is required before the brand name combination packages will be approved unless one of the exceptions on the PA form is present.
HEPATITIS B TREATMENTS			
	EPIVIR HBV (lamivudine) HEPSERA (adefovir) TYZEKA (telbivudine)	BARACLUDE (entecavir)	A thirty (30) day trial of one of the preferred agents is required before the non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
HEPATITIS C TREATMENTS^{CL}			
	INCIVEK (telaprevir) ^{CL} PEGASYS (pegylated interferon) PEG-INTRON (pegylated interferon)	COPEGUS (ribavirin) INFERGEN (consensus interferon) REBETOL (ribavirin)	Patients starting therapy in this class must try the preferred agent of a dosage form before a non-



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	ribavirin VICTRELIS (boceprevir) ^{CL}	RIBAPAK DOSEPACK (ribavirin) RIBASPHERE (ribavirin)	preferred agent of that dosage form will be authorized. See additional criteria for Incivek and Victrelis at http://www.dhr.wv.gov/bms/Pharmacy/Pages/pac.aspx
HYPERURICEMIA AND GOUT AGENTS			
ANTIMITOTICS			
		COLCRYS (colchicine)*	A thirty-day trial of one of the preferred agents for the prevention of gouty arthritis attacks (colchicine/probenecid, probenecid, or allopurinol) is required before a non-preferred agent will be approved unless one of the exceptions on the PA form is present. *In the case of acute gouty attacks, a 10-day supply (20 tablets) of Colcris will be approved per 90 days.
ANTIMITOTIC-URICOSURIC COMBINATION			
	colchicine/probenecid		
URICOSURIC			
	probenecid		
XANTHINE OXIDASE INHIBITORS			
	allopurinol	ULORIC (febuxostat) ZYLOPRIM (allopurinol)	
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS			
INJECTABLE			



BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		BYETTA (exenatide) SYMLIN (pramlintide) VICTOZA (liraglutide)	<p>Byetta, Symlin, and Victoza will be subject to the following clinical edits:</p> <p>Byetta and Victoza will be approved with a previous history of a thirty (30) day trial of an oral agent (sulfonylurea, thiazolidinedione (TZD) and/ or metformin) and no evidence of concurrent insulin therapy.</p> <p>Symlin- History of insulin utilization in the past 90 days. No gaps in insulin therapy greater than 30 days.</p>
ORAL^{AP}			
	JANUMET (sitagliptin/metformin) JANUVIA (sitagliptin) JUVISYNC (sitagliptin/simvastatin) KOMBIGLYZE XR (saxagliptin/metformin) ONGLYZA (saxagliptin) TRADJENTA (linagliptin)		<p>Januvia/Janumet/Juvisync, Onglyza/Kombiglyze XR and Tradjenta will be subject to the following edits:</p> <ol style="list-style-type: none"> 1.Previous history of a 30-day trial of an oral agent (sulfonylurea, thiazolidinedione (TZD) or metformin) 2.Onglyza/Kombiglyze XR and Tradjenta will not be approved for concurrent use with insulin. 3.Januvia/Janumet /Juvisync will be approved for concurrent use with insulin for six (6) month intervals. For re-authorization, HgBA1C levels must be less than or equal (\leq) to 7. Current laboratory values must be submitted.
HYPOGLYCEMICS, INSULINS			



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	HUMALOG (insulin lispro) vials HUMALOG PEN/KWIKPEN (insulin lispro) HUMALOG MIX (insulin lispro/lispro protamine) vials only HUMULIN (insulin) vials only LANTUS (insulin glargine) all forms LEVEMIR (insulin detemir) all forms NOVOLIN (insulin) all forms NOVOLOG (insulin aspart) all forms NOVOLOG MIX all forms (insulin aspart/aspart protamine)	APIDRA (insulin glulisine) ^{AP} HUMALOG MIX PENS (insulin lispro/lispro protamine) HUMULIN PEN (insulin)	To receive Apidra, patients must meet the following criteria: <ol style="list-style-type: none"> 1. be 4 years or older; 2. be currently on a regimen including a longer-acting or basal insulin. 3. have had a trial of a similar preferred agent, Novolog or Humalog, with documentation that the desired results were not achieved.
HYPOGLYCEMICS, MEGLITINIDES			
MEGLITINIDES			
	PRANDIN (repaglinide) STARLIX (nateglinide)	nateglinide	A thirty (30) day trial of the preferred agent is required before a non-preferred agent will be authorized, unless one of the exceptions on the PA form is present.
MEGLITINIDE COMBINATIONS			
		PRANDIMET (repaglinide/metformin)	
HYPOGLYCEMICS, MISCELLANEOUS			
	WELCHOL (colesevelam) ^{AP}		Welchol will be approved for add-on therapy for type 2 diabetes when there is a previous history of a 30-day trial of an oral agent (sulfonylurea, thiazolidinedione (TZD) or metformin).
HYPOGLYCEMICS, TZDS			
THIAZOLIDINEDIONES			
	ACTOS (pioglitazone)	AVANDIA (rosiglitazone) ^{AP}	Treatment naïve patients require a two (2) week trial of Actos before Avandia will be authorized, unless one of the exceptions on the PA form is present.
TZD COMBINATIONS			



BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		ACTOPLUS MET (pioglitazone/ metformin) ACTOPLUS MET XR (pioglitazone/ metformin) AVANDAMET (rosiglitazone/metformin) ^{AP} AVANDARYL (rosiglitazone/glimepiride) ^{AP} DUETACT (pioglitazone/glimepiride)	Patients are required to use the components of Actoplus Met and Duetact separately. Exceptions will be handled on a case-by-case basis.
IMPETIGO AGENTS (Topical)			
	bacitracin gentamicin sulfate mupirocin	ALTABAX (retapamulin) BACTROBAN (mupirocin) CORTISPORIN (bacitracin/neomycin/ polymyxin/HC)	Ten (10) day trials of at least one preferred agent, including the generic formulation of a requested non-preferred agent, are required before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
INTRANASAL RHINITIS AGENTS^{AP}			
ANTICHOLINERGICS			
	ipratropium	ATROVENT(ipratropium)	Thirty (30) day trials of the preferred nasal anti-cholinergic, an antihistamine, and corticosteroid groups are required before a non-preferred anti-cholinergic will be approved unless one of the exceptions on the PA form is present.
ANTI-HISTAMINES			
	ASTELIN (azelastine) PATANASE (olopatadine)	ASTEPRO (azelastine) azelastine	Thirty (30) day trials of both preferred intranasal antihistamines and a thirty (30) day trial of one of the preferred intranasal corticosteroids are required before the non-preferred agent will be approved unless one of the exceptions on the PA form is present.
CORTICOSTEROIDS			
	fluticasone propionate NASACORT AQ (triamcinolone) NASONEX (mometasone)	BECONASE AQ (beclomethasone) flunisolide FLONASE (fluticasone propionate) NASALIDE (flunisolide)	Thirty (30) day trials of each preferred agent in the corticosteroid group are required before a non-preferred corticosteroid agent will



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		NASAREL (flunisolide) OMNARIS (ciclesonide) RHINOCORT AQUA (budesonide) triamcinolone VERAMYST (fluticasone furoate)	be authorized unless one of the exceptions on the PA form is present.
LEUKOTRIENE MODIFIERS			
	ACCOLATE (zafirlukast) SINGULAIR (montelukast)	zafirlukast ZYFLO (zileuton)	Thirty (30) day trials each of the preferred agents are required before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
LIPOTROPICS, OTHER (Non-statins)^{AP}			
BILE ACID SEQUESTRANTS			
	cholestyramine colestipol	COLESTID (colestipol) QUESTRAN (cholestyramine) WELCHOL (colesevelam)	<p>A twelve (12) week trial of one of the preferred agents is required before a non-preferred agent in the corresponding category will be authorized.</p> <p>Welchol will be approved for add-on therapy for type 2 diabetes when there is a previous history of a 30-day trial of an oral agent (sulfonylurea, thiazolidinedione (TZD) or metformin). See HYPOGLYCEMICS, MISCELLANEOUS.</p>
CHOLESTEROL ABSORPTION INHIBITORS			
		ZETIA (ezetimibe)	<p>Zetia, as monotherapy, will only be approved for patients who cannot take statins or other preferred agents. AP does not apply.</p> <p>Zetia will be approved for add-on therapy only after an insufficient response to the maximum tolerable dose of a statin after 12 weeks of therapy. AP does not apply.</p>



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
FATTY ACIDS			
	LOVAZA (omega-3-acid ethyl esters) ^{AP}		Lovaza will be approved when the patient is intolerant or not responsive to, or not a candidate for nicotinic acid or fibrate therapy.
FIBRIC ACID DERIVATIVES			
	fenofibrate 54mg & 160mg fenofibrate micronized 67mg, 134mg & 200mg gemfibrozil TRICOR (fenofibrate nanocrystallized) TRILIPIX (fenofibric acid)	ANTARA (fenofibrate) FENOGLIDE (fenofibrate) FIBRICOR (fenofibric acid) fenofibrate nanocrystallized 145mg LIPOFEN (fenofibrate) LOFIBRA (fenofibrate) LOPID (gemfibrozil) TRIGLIDE (fenofibrate)	
NIACIN			
	niacin NIASPAN (niacin)	NIACELS (niacin) NIACOR (niacin) NIADELAY (niacin) SLO-NIACIN (niacin)	
LIPOTROPICS, STATINS^{AP}			
STATINS			
	CRESTOR (rosuvastatin) LESCOL (fluvastatin) LESCOL XL (fluvastatin) LIPITOR (atorvastatin) lovastatin pravastatin simvastatin ^{CL*}	ALTOPREV (lovastatin) atorvastatin LIVALO (pitavastatin) MEVACOR (lovastatin) PRAVACHOL (pravastatin) ZOCOR (simvastatin) ^{CL*}	Twelve (12) week trials each of two (2) of the preferred statins, including the generic formulation of a requested non-preferred agent, are required before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. *Zocor/simvastatin 80mg tablets will require a clinical PA
STATIN COMBINATIONS			
	ADVICOR (lovastatin/niacin) amlodipine / atorvastatin SIMCOR (simvastatin/niacin ER)	CADUJET (atorvastatin/amlodipine) VYTORIN (simvastatin/ ezetimibe) ^{CL*}	Vytorin will be approved only after an insufficient response to the maximum tolerable dose of Lipitor (atorvastatin) or Crestor



BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
			<p>(rosuvastatin) after 12 weeks, unless one of the exceptions on the PA form is present.</p> <p>*Vytorin 80/10mg tablets will require a clinical PA</p>
MACROLIDES/KETOLIDES (Oral)			
KETOLIDES			
		KETEK (telithromycin)	Requests for telithromycin will be authorized if there is documentation of the use of any antibiotic within the past 28 days.
MACROLIDES			
	azithromycin clarithromycin erythromycin	BIAXIN (clarithromycin) BIAXIN XL (clarithromycin) clarithromycin ER E.E.S. (erythromycin ethylsuccinate) E-MYCIN (erythromycin) ERYC (erythromycin) ERYPED (erythromycin ethylsuccinate) ERY-TAB (erythromycin) ERYTHROCIN (erythromycin stearate) erythromycin estolate PCE (erythromycin) ZITHROMAX (azithromycin) ZMAX (azithromycin)	Five (5) day trials each of the preferred agents are required before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
MULTIPLE SCLEROSIS AGENTS^{CL, AP}			
INTERFERONS			
	AVONEX (interferon beta-1a) BETASERON (interferon beta-1b) REBIF (interferon beta-1a)	EXTAVIA (interferon beta-1b)	A 30-day trial of a preferred agent will be required before a non-preferred agent will be approved.
NON-INTERFERONS			
	COPAXONE (glatiramer)	AMPYRA (dalfampridine) ^{CL*} GILENYA (fingolimod) ^{CL**} TYSABRI (natalizumab) ^{***}	A 30-day trial of the preferred agent will be required before a non-preferred agent will be approved. *Amypra will be prior authorized if



BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
			<p>the following conditions are met:</p> <ol style="list-style-type: none"> 1. Diagnosis of multiple sclerosis 2. No history of seizures 3. No evidence of moderate or severe renal impairment 4. Initial prescription will be approved for 30 days only. <p>** Gilenya: PA Criteria</p> <ol style="list-style-type: none"> 1) A diagnosis of a relapsing form of multiple sclerosis AND 2) Medication is prescribed by a neurologist AND 3) History of a thirty (30) trial of one of the preferred agents for multiple sclerosis unless <i>one of</i> the exceptions on the PA form is present AND 4) Dosage is limited to one tablet per day. (AP does not apply.) <p>***Tysabri will only be <i>approved</i> for members who are enrolled in the TOUCH Prescribing Program. AP does not apply.</p>
MUSCLE RELAXANTS (Oral)^{AP}			
ACUTE MUSCULOSKELETAL RELAXANT AGENTS			
	<p>chlorzoxazone cyclobenzaprine methocarbamol</p>	<p>AMRIX (cyclobenzaprine) carisoprodol carisoprodol/ASA carisoprodol/ASA/codeine cyclobenzaprine ER FEXMID (cyclobenzaprine) FLEXERIL (cyclobenzaprine) LORZONE (chlorzoxazone) metaxalone methocarbamol/ASA orphenadrine</p>	<p>Thirty (30) day trials of the preferred acute musculoskeletal relaxants are required before a non-preferred acute musculoskeletal agent will be approved, with the exception of carisoprodol.</p> <p>Thirty (30) day trials of the preferred acute musculoskeletal relaxants and Skelaxin are required before carisoprodol will be approved.</p>



BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		orphenadrine/ASA/caffeine PARAFON FORTE DSC (chlorzoxazone) ROBAXIN (methocarbamol) SKELAXIN (metaxalone) SOMA (carisoprodol) SOMA COMPOUND (carisoprodol /ASA) SOMA COMP w/ COD (carisoprodol/ASA/ codeine)	
MUSCULOSKELETAL RELAXANT AGENTS USED FOR SPASTICITY			
	baclofen dantrolene tizanidine	DANTRIUM (dantrolene) ZANAFLEX (tizanidine)	Thirty (30) day trials of the preferred skeletal muscle relaxants associated with the treatment of spasticity (are required before non-preferred agents will be approved unless one of the exceptions on the PA form is present.
NSAIDS^{AP}			
NON-SELECTIVE			
	diclofenac etodolac fenoprofen flurbiprofen ibuprofen (Rx and OTC) INDOCIN (indomethacin) (suspension only) indomethacin ketorolac naproxen (Rx only) oxaprozin sulindac	ADVIL (ibuprofen) ANAPROX (naproxen) ANSAID (flurbiprofen) CAMBIA (diclofenac) CATAFLAM (diclofenac) CLINORIL (sulindac) DAYPRO (oxaprozin) FELDENE (piroxicam) INDOCIN (indomethacin) ketoprofen ketoprofen ER LODINE (etodolac) meclofenamate mefenamic acid MOTRIN (ibuprofen) nabumetone NALFON (fenoprofen) NAPRELAN (naproxen) NAPROSYN (naproxen) NUPRIN (ibuprofen) ORUDIS (ketoprofen) piroxicam PONSTEL (meclofenamate)	Thirty (30) day trials of each of the preferred agents are required before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID**

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		SPRIX (ketorolac) tolmetin VOLTAREN (diclofenac) ZIPSOR (diclofenac potassium)	
NSAID/GI PROTECTANT COMBINATIONS			
		ARTHROTEC (diclofenac/misoprostol) VIMOVO (naproxen/esomeprazole)	
COX-II SELECTIVE			
	meloxicam	CELEBREX (celecoxib) ^{CL} MOBIC (meloxicam)	Requests for COX-2 Inhibitor agents will be authorized if the following criteria are met: Agent is requested for treatment of a chronic condition, and a. Patient is greater than or equal to 70 years of age, or b. Patient is currently on anticoagulation therapy, or c. Patient has a history or risk of a serious GI complication.
OPHTHALMIC ANTIBIOTICS (FLUOROQUINOLONES & SELECT MACROLIDES)^{AP}			
	ciprofloxacin MOXEZA (moxifloxacin) ofloxacin VIGAMOX (moxifloxacin) **The American Academy of Ophthalmology guidelines on treating bacterial conjunctivitis recommend as first line treatment options: erythromycin ointment, sulfacetamide drops, or polymyxin/trimethoprim drops. Alternative treatments include bacitracin ointment, sulfacetamide ointment, polymyxin/bacitracin	AZASITE (azithromycin) BESIVANCE (besifloxacin) CILOXAN (ciprofloxacin) levofloxacin OCUFLOX (ofloxacin) QUIXIN (levofloxacin) ZYMAXID (gatifloxacin)	Five (5) day trials of each of the preferred agents are required before non-preferred agents will be authorized unless one of the exceptions on the PA form is present. **A prior authorization is required for the fluoroquinolone agents for patients under 21 years of age unless there has been a trial of a first line treatment option within the



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID**

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	ointment, fluoroquinolone drops, or azithromycin drops. All generic forms of ophthalmic erythromycin, sulfacetamide, and polymyxin/trimethoprim, polymyxin/bacitracin and bacitracin are preferred.		past 10 days.
OPHTHALMIC ANTI-INFLAMMATORIES			
	flurbiprofen ketorolac 0.4% NEVANAC (nepafenac)	ACULAR LS (ketorolac) ACUVAIL 0.45% (ketorolac tromethamine) ^{AP} BROMDAY (bromfenac) diclofenac ^{AP} DUREZOL (difluprednate) ^{AP} LOTEMAX (loteprednol) VEXOL (rimexolone) XIBROM (bromfenac)	Five (5) day trials of each of the preferred ophthalmic anti-inflammatory agents are required before nonpreferred agents will be authorized unless one of the exceptions on the PA form is present.
OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS			
	ALWAY (ketotifen) ALREX (loteprednol) cromolyn ketorolac 0.5% PATADAY (olopatadine) PATANOL (olopatadine) ZADITOR OTC (ketotifen)	ACULAR (ketorolac) ALAMAST (pemirolast) ^{AP} ALOCRIL (nedocromil) ^{AP} ALOMIDE (lodoxamide) ^{AP} azelastine BEPREVE (bepotastine) ^{AP} CROLOM (cromolyn) ^{AP} DUREZOL (difuprednate) ^{NR} ELESTAT (epinastine) ^{AP} EMADINE (emedastine) ^{AP} epinastine ketotifen LASTACAFT (alcaftadine) OPTICROM (cromolyn) ^{AP} OPTIVAR (azelastine) ZYRTEC ITCHY EYE (ketotifen) ^{AP}	Thirty (30) day trials of each of three (3) of the preferred agents are required before non-preferred agents will be authorized, unless one of the exceptions on the PA form is present.
OPHTHALMICS, GLAUCOMA AGENTS			
COMBINATION AGENTS			
	COMBIGAN (brimonidine/timolol) dorzolamide/timolol	COSOPT (dorzolamide/timolol)	Authorization for a non-preferred agent will only be given if there is an allergy to the preferred agents.
BETA BLOCKERS			



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	betaxolol BETOPTIC S (betaxolol) carteolol levobunolol metipranolol timolol	BETAGAN (levobunolol) BETIMOL (timolol) ISTALOL (timolol) OPTIPRANOLOL (metipranolol) TIMOPTIC (timolol)	
CARBONIC ANHYDRASE INHIBITORS			
	AZOPT (brinzolamide) dorzolamide	TRUSOPT (dorzolamide)	
PARASYMPATHOMIMETICS			
	CARBOPTIC (carbachol) ISOPTO CARBACHOL (carbachol) PHOSPHOLINE IODIDE (echothiophate iodide) pilocarpine	ISOPTO CARPINE (pilocarpine) PILOPINE HS (pilocarpine)	
PROSTAGLANDIN ANALOGS			
	latanoprost LUMIGAN (bimatoprost) TRAVATAN-Z (travoprost)	XALATAN (latanoprost)	
SYMPATHOMIMETICS			
	ALPHAGAN P (brimonidine) brimonidine 0.2% dipivefrin	brimonidine 0.15% PROPINE (dipivefrin)	
OTIC FLUOROQUINOLONES^{AP}			
	CIPRODEX (ciprofloxacin/dexamethasone)* ofloxacin	CIPRO HC (ciprofloxacin/hydrocortisone) CETRAXAL 0.2% SOLUTION (ciprofloxacin) FLOXIN (ofloxacin)	Five (5) day trials of each of the preferred agents are required before a non-preferred agent will be approved unless one of the exceptions on the PA form is present. *Ciprodex is limited to patients 8 years of age and younger. Age exceptions will be handled on a case-by-case basis.



BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
PANCREATIC ENZYMES^{AP}			
	CREON ZENPEP	PANCREAZE PANCRELIPASE 5000	A thirty (30) day trial of a preferred agent is required before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. Non-preferred agents will be approved for members with cystic fibrosis.
PARATHYROID AGENTS^{AP}			
	calcitriol HECTOROL (doxercalciferol) vitamin d 2 (ergocalciferol) (Rx and OTC)* vitamin d 3 (cholecalciferol) (Rx and OTC)* ZEMPLAR (paricalcitol)	DRISDOL (ergocalciferol) ROCALTROL (calcitriol) SENSIPAR (cinacalcet)	A thirty (30) day trial of a preferred agent will be required before a non-preferred agent will be approved. *See Covered List
PEDICULICIDES/SCABICIDES (Topical)^{AP}			
	OVIDE (malathion) permethrin (Rx and OTC) pyrethrins-piperonyl butoxide	EURAX (crotamiton) lindane LYCELLE (topical gel) malathion 0.5% lotion NATROBA (spinosad) ULESFIA 5% LOTION (benzyl alcohol)	Trials of the preferred agents (which are age and weight appropriate) are required before non-preferred agents will be approved unless one of the exceptions on the PA form is present.
PHOSPHATE BINDERS^{AP}			
	calcium acetate FOSRENOL (lanthanum) RENAGEL (sevelamer) RENVELA (sevelamer carbonate)	ELIPHOS (calcium acetate) PHOSLYRA (calcium acetate)	Thirty (30) day trials of at least two preferred agents are required unless one of the exceptions on the PA form is present.
PLATELET AGGREGATION INHIBITORS^{AP}			
	AGGRENOX (dipyridamole/ASA) cilostazol PLAVIX (clopidogrel)	BRILINTA (ticagrelor) dipyridamole EFFIENT (prasugrel) PERSANTINE (dipyridamole) PLETAL (cilostazol) TICLID (ticlopidine) ticlopidine	A thirty (30) day trial of a preferred agent is required before a non-preferred agent will be approved unless one of the exceptions on the PA form is present. Effient will be approved for acute coronary syndrome when it is to be managed by acute or delayed



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID**

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		PRIMACARE RENATE/RENATE DHA SELECT-OB TANDEM DHA/TANDEM OB	
PROTON PUMP INHIBITORS^{AP}			
	DEXILANT (dexlansoprazole) omeprazole pantoprazole	ACIPHEX (rabeprazole) lansoprazole NEXIUM (esomeprazole) NEXIUM PACKETS (esomeprazole) omeprazole/sodium bicarbonate PREVACID capsules (lansoprazole) PREVACID Solu-Tabs (lansoprazole) PRILLOSEC (omeprazole) PROTONIX (pantoprazole) ZEGERID OTC (omeprazole)	Sixty (60) day trials of each of the preferred agents, inclusive of a concurrent thirty (30) day trial at the maximum dose of an H ₂ antagonist are required before a non-preferred agent will be approved unless one of the exceptions on the PA form is present Prior authorization is not required for Prevacid Solu-Tabs for patients ≤8 years of age.
PSORIATIC AGENTS - TOPICAL			
	calcipotriene ointment DOVONEX (calcipotriene) TAZORAC (tazarotene)	calcipotriene solution TACLONEX (calcipotriene/betamethasone) VECTICAL (calcitriol)	Thirty (30) day trials of two (2) preferred unique chemical entities are required before non-preferred agents will be approved unless one of the exceptions on the PA form is present.
PULMONARY ANTIHYPERTENSIVES - ENDOTHELIN RECEPTOR ANTAGONISTS^{CL}			
	LETAIRIS (ambrisentan)	TRACLEER (bosentan)	Letairis will be approved for the treatment of pulmonary artery hypertension (PAH) World Health Organization (WHO) Group I to improve exercise ability and decrease the rate of clinical deterioration. Tracleer will be approved for the treatment of pulmonary artery hypertension (PAH) (WHO Group I) in patients with World Health Organization (WHO) Class II, III, or IV symptoms to improve exercise capacity and decrease the rate of



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
			clinical deterioration AND when there has been a failure with Letairis.
PULMONARY ANTIHYPERTENSIVES – PDE5s^{CL}			
	ADCIRCA (tadalafil) REVATIO (sildenafil)		
PULMONARY ANTIHYPERTENSIVES – PROSTACYCLINS^{CL}			
	epoprostenol VENTAVIS (iloprost)	FLOLAN (epoprostenol) REMODULIN (treprostinil sodium) TYVASO (treprostinil)	Ventavis will only be approved for the treatment of pulmonary artery hypertension (WHO Group 1) in patients with NYHA Class III or IV symptoms. Remodulin and Tyvaso will be approved only after a 30-day trial of Ventavis unless one of the exceptions on the PA form is present.
SEDATIVE HYPNOTICS^{AP}			
BENZODIAZEPINES			
	temazepam	DALMANE (flurazepam) DORAL (quazepam) estazolam flurazepam HALCION (triazolam) RESTORIL (temazepam) triazolam	Fourteen (14) day trials of the preferred agents in both categories are required before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
OTHERS			
	zolpidem	AMBIEN (zolpidem) AMBIEN CR (zolpidem) chloral hydrate EDLUAR SL (zolpidem) LUNESTA (eszopiclone) ROZEREM (ramelteon) SILENOR (doxepin) SOMNOTE (chloral hydrate) SONATA (zaleplon)	



BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		zaleplon zolpidem tartrate ER ZOLPIMIST SPRAY (zolpidem)	
STIMULANTS AND RELATED AGENTS			
AMPHETAMINES			
	amphetamine salt combination dextroamphetamine VYVANSE (lisdexamfetamine)	ADDERALL (amphetamine salt combination) ADDERALL XR (amphetamine salt combination) amphetamine salt combination ER DESOXYN (methamphetamine) DEXEDRINE (dextroamphetamine) DEXTROSTAT (dextroamphetamine) methamphetamine PROCENTRA (dextroamphetamine) ^{NR}	<p>Members currently utilizing Adderall XR as of 1/1/2012 may continue use until 6/30/2012.</p> <p>Except for Strattera, PA is required for adults >18 years.</p> <p>One of the preferred agents in each group (amphetamines and non-amphetamines) must be tried for thirty (30) days before a non-preferred agent will be authorized.</p> <p>Thirty (30) day trials of at least three (3) antidepressants are required before amphetamines will be approved for depression.</p> <p>Provigil will only be approved for patients >16 years of age with a diagnosis of narcolepsy.</p>
NON-AMPHETAMINE			
	CONCERTA (methylphenidate) DAYTRANA (methylphenidate) FOCALIN (dexmethylphenidate) FOCALIN XR (dexmethylphenidate) guanfacine INTUNIV (guanfacine extended-release) METADATE CD (methylphenidate) methylphenidate methylphenidate ER (Generic Ritalin SR, Metadate ER, Methylin ER) STRATTERA (atomoxetine)	dexmethylphenidate KAPVAY ER (clonidine) METADATE ER (methylphenidate) methylphenidate ER (Generic Concerta) methylphenidate ER (Generic Ritalin LA) NUVIGIL (armodafinil) pemoline PROVIGIL (modafinil) RITALIN (methylphenidate) RITALIN LA (methylphenidate) RITALIN-SR (methylphenidate)	<p>Strattera will not be approved for concurrent administration with amphetamines or methylphenidates, except for 30 days or less for tapering purposes. Strattera is limited to a maximum of 100mg per day.</p> <p>Kapvay will be approved if the following criteria are met:</p> <ol style="list-style-type: none"> 1. Fourteen (14) day trials of at least one preferred product from the amphetamine and non-amphetamine class and



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID**

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
			2. A fourteen (14) day trial of Strattera and 3. A fourteen (14) day trial of clonidine (for Kapvay) unless one of the exceptions on the PA form is present or 4. In cases of a diagnosis of Tourette's syndrome, tics, autism or disorders included in the autism spectrum, only a fourteen (14) day trial of clonidine (for Kapvay) is required for approval.
TETRACYCLINES^{AP}			
	doxycycline hyclate minocycline capsules tetracycline	ADOXA (doxycycline monohydrate) demeclocycline* DORYX (doxycycline hyclate) doxycycline hyclate delayed release doxycycline monohydrate DYNACIN (minocycline) MINOCIN (minocycline) minocycline SR capsules minocycline tablets MONODOX (doxycycline monohydrate) ORACEA (doxycycline monohydrate) SOLODYN (minocycline) SUMYCIN (tetracycline) VIBRAMYCIN SYRUP (doxycycline calcium) VIBRAMYCIN (doxycycline hyclate) VIBRAMYCIN (doxycycline monohydrate) VIBRA-TABS (doxycycline hyclate)	A ten-day trial of each of the preferred agents is required before a non-preferred agent will be approved. *Demeclocycline will be approved for conditions caused by susceptible strains of organisms designated in the product information supplied by the manufacturer. A C&S report must accompany this request. *Demeclocycline will also be approved for SIADH.
ULCERATIVE COLITIS AGENTS^{AP}			
ORAL			
	APRISO (mesalamine) ASACOL (mesalamine) 400mg COLAZAL (balsalazide) DIPENTUM (olsalazine) PENTASA (mesalamine) 250mg sulfasalazine	ASACOL HD (mesalamine) 800mg AZULFIDINE (sulfasalazine) balsalazide LIALDA (mesalamine) PENTASA (mesalamine) 500mg	Thirty (30) day trials of each of the preferred agents of a dosage form must be tried before a non-preferred agent of that dosage form will be authorized unless one of the exceptions on the PA form is



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
			present.
	RECTAL		
	CANASA (mesalamine) mesalamine	SF ROWASA (mesalamine)	
VAGINAL ANTIBACTERIALS			
	clindamycin cream METROGEL (metronidazole)	AVC (sulfanilamide) CLEOCIN CREAM (clindamycin) CLEOCIN OVULE (clindamycin) CLINDESSE (clindamycin) metronidazole VANDAZOLE (metronidazole)	A trial, the duration of the manufacturer's recommendation, of each of the preferred agents is required before a non-preferred agent will be approved unless one of the exceptions on the PA form is present.
MISC BRAND/GENERIC			
	CLONIDINE		
	CATAPRES-TTS (clonidine) clonidine tablets	clonidine patch NEXICLON XR (clonidine) CATAPRES TABLETS (clonidine)	A thirty (30) day trial of each preferred unique chemical entity in the corresponding therapeutic category is required before a non-preferred agent will be authorized.
	MEGESTROL		
	MEGACE ES (megestrol) megestrol	MEGACE (megestrol)	
	SUBLINGUAL NITROGLYCERIN		
	nitroglycerin sublingual NITROSTAT SUBLINGUAL (nitroglycerin)	NITROLINGUAL (nitroglycerin) NITROMIST (nitroglycerin)	
	OCTREOTIDE		
	SANDOSTATIN (octreotide)	octreotide	
	EPINEPHRINE		
	TWINJECT (epinephrine) EPIPEN (epinephrine)		



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
04/01/12
Version 2012.5

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ORAL CONTRACEPTIVES			
	YASMIN (ethinyl estradiol/drospirenone)	BEYAZ (ethinyl estradiol/drospirenone/levomefolate) Gianvi (ethinyl estradiol/drospirenone) Ocella (ethinyl estradiol/drospirenone) YAZ (ethinyl estradiol/drospirenone)	
SUBSTANCE ABUSE TREATMENTS			
	SUBOXONE (buprenorphine) FILM ^{CL}	SUBOXONE (buprenorphine) TABS ^{CL}	Suboxone PA criteria is available at http://www.dhr.wv.gov/bms/Pharmacy/Pages/pac.aspx

DRAFT